Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Novel engineered cytokines for human therapy

Project description

Novel synthesis of therapeutically relevant cytokines

Cytokines are proteins implicated in cell communication during immune responses and control the activity of immune cells. They exert both local and systemic effects and have been used to treat cancer and promote tissue regeneration. Despite their great therapeutic potential, cytokine administration causes adverse effects while they exhibit reduced efficacy and serum half-life. To address this problem, the ERC-funded Cytodesign project proposes a protein design strategy relevant to the synthesis of therapeutically relevant cytokines. The Cytodesign technological platform generates products with overall improved pharmacodynamics and pharmacokinetics including increased stability and specificity.

Objective

Cytokines are biomolecules of great potential interest for human therapy. They modulate the immune system and play an important role in cancer, inflammation, immune response and tissue regeneration. Despite their great potential, there are only a handful of cytokines approved for therapeutic purposes. This is because many of them can have adverse side effects as they usually target different cell types, which adds to their low serum half-life, high production costs, or lack of physiological efficacy. Different methods have been proposed to improve the pharmacodynamics and pharmacokinetics of selected cytokines. However, other properties do also need improvement, such as achieving effective local concentration at the target site; promoting the right activity in cytokines with dual functionality and decreasing toxicity by removing binding to unwanted cell types. To help solving these issues, we have developed a new protein design strategy that can be applied to all helix-bundle cytokines, many of which have been shown to be therapeutically relevant. The resulting products are uniquely modified cytokines with improved properties. Amongst such properties, our products show increase stability, higher affinity and specificity for their target receptors and should have reduced toxicity, all of which translate into greater safety and efficacy. We have initial evidence both (in vitro and in vivo) of the superiority of our designs over conventional cytokines, and in this project we will fully validate our technological platform and advance in the development of a business plan following the advice of several venture capital and pharma companies contacted to date, with the idea of laying the basis for the creation of a new start-up company.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2022-POC2

See all projects funded under this call

Host institution

FUNDACIO CENTRE DE REGULACIO GENOMICA
Net EU contribution
€ 150 000,00
Address
CARRER DOCTOR AIGUADER 88
08003 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)